Lexaria Bioscience Corp.
No SEC Form 4 filings for $LEXX in the last 30 days.
See all $LEXX insider activity →Lexaria Bioscience Corp. (NASDAQ: LEXX) announced a strong cash position following a $7.9M tax refund and institutional financing at $12.92/share. The company has $4.60/share in cash, extending its runway through 2027. CEO Rich Christopher noted recent stock price pressure but plans to execute business strategy. Lexaria expects to reduce R&D costs in 2027 through partnerships.
Lexaria Bioscience Corp. (NASDAQ: LEXX) closed the exercise of warrants, raising $5.9 million. The company issued new Series A and B warrants. Proceeds will be used for working capital and corporate purposes. H.C. Wainwright & Co. acted as the placement agent.
Lexaria Bioscience Corp. (LEXX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds Tuesday, 08 September 2026 08:00 AM Topic: Financing KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Le
Over the past 7 days, AlphAI's AI scored 1 news story mentioning LEXX (Lexaria Bioscience Corp.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent LEXX coverage spans corporate actions, technology and financial news.
The fresh capital improves liquidity and may support near‑term price stability, but the disclosed “aggressive trading” suggests short‑term volatility.
The capital raise provides short‑term liquidity for working capital but is modest in scale.
The cash infusion modestly improves liquidity but is unlikely to move the stock significantly.
Warrant repricing caused a steep sell‑off.
The rebate adds non‑dilutive cash to the balance sheet, modestly improving liquidity.
AlphAI scores every news story that mentions LEXX with an AI model for sentiment and relevance, and aggregates insider trades from Lexaria Bioscience Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lexaria Bioscience Corp. (NASDAQ: LEXX) announced a strong cash position following a $7.9M tax refund and institutional financing at $12.92/share. The company has $4.60/share in cash, extending its runway through 2027. CEO Rich Christopher noted recent stock price pressure but plans to execute business strategy. Lexaria expects to reduce R&D costs in 2027 through partnerships.
1 min readLexaria Bioscience Corp. (NASDAQ: LEXX) closed the exercise of warrants, raising $5.9 million. The company issued new Series A and B warrants. Proceeds will be used for working capital and corporate purposes. H.C. Wainwright & Co. acted as the placement agent.
2 min readLexaria Bioscience Corp. (LEXX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds Tuesday, 08 September 2026 08:00 AM Topic: Financing KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Le
1 min readU.S. stocks fell Tuesday, with the Dow Jones dropping 450 points. The NFIB Small Business Optimism Index declined to 98.7 in August. PDS Biotechnology (PDSB) shares surged 178% after raising $22.55 million in equity funding. Energy shares rose 1.4%, while healthcare stocks fell 2.2%.
3 min readLexaria Bioscience Corp. (NASDAQ: LEXX) received a AUD$3.67 million (USD$2.6 million) tax rebate from the Australian Tax Office for its 2025 R&D study. The funds will support future R&D in Australia, according to the company. The rebate was not included in previous financial statements but will be accounted for in the upcoming 10-K filing.
1 min readLexaria Bioscience Corp. (NASDAQ: LEXX) reported that its DehydraTECH 3.0 technology significantly improved drug absorption in animal studies. The DHT3.0-amycretin tablet showed a 481.14% increase in bioavailability compared to the DHT2.0 version, while the DHT3.0-retatrutide tablet demonstrated a 4,552.20% improvement. The company aims to use these findings to attract partners in the GLP-1 drug sector.
2 min readLexaria Bioscience (NASDAQ:LEXX) said it signed a material transfer agreement with Pegbio Co., Ltd. to test Lexaria’s DehydraTECH drug-delivery technology using a proprietary Pegbio GLP-1 molecule for GLP-1 industry applications. Pegbio will supply the molecule for animal pharmacokinetic studies. Lexaria plans to update after study completion.
2 min readLexaria Bioscience Corp. (Nasdaq: LEXX) said its reverse stock split will take effect at 12:01 a.m. ET on Aug. 3, 2026, on a 1-for-15 basis, to help regain Nasdaq compliance with the $1.00 minimum bid rule. Shares will trade under LEXX with a new CUSIP. Authorized shares and convertible securities will be adjusted.
3 min readLexaria Bioscience Corp. (NASDAQ:LEXX) said it held multiple meetings with potential pharma partners at the 2026 BIO International Convention in San Diego, aiming to form partnership arrangements. The company cited increased GLP-1 discussions focused on drug safety and adverse-event profiles, and renewed interest in its DehydraTECH-CBD and DehydraTECH-nicotine programs.
2 min readLexaria Bioscience (NASDAQ: LEXX) said animal Study GLP-1-A26-1 began dosing on June 10, 2026, on schedule, using Sprague-Dawley rats to test DehydraTECH-semaglutide and DehydraTECH-CBD formulations. Results are expected in early September. The company also reported an Australian patent grant (No. 2023302884) granted June 11, 2026, valid until April 25, 2043.
3 min read
